UNSPSC 51171925: Rebamipide

This classification denotes an anti-ulcer agent with the molecular formula C19H15ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LR583V32ZR, chemically known as 4-quinolinepropanoic acid, 1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-, (+-)- but generally known as rebamipide, which bears US NIH Compound Identifier 5042. European Medicines Agency schedules Rebamipide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10267MIG.

UNSPSC 51171925 Rebamipide is a Commodity code, but the recent state and local procurement activity under this code shows no direct sourcing of rebamipide itself. Instead, the opportunities posted reflect a broad mismatch: Collin County in Texas is soliciting offender specimen collection and drug testing services (immunoassay screening with LC/MS/MS or GC/MS confirmation, oral fluid and hair testing, and result reporting); the Texas Health and Human Services Commission issued a Request for Information on therapeutic pharmacy initiatives and direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing contracts for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers. None of these opportunities explicitly specify rebamipide as a product or component of the work being procured, and the character of the solicitations—spanning forensic drug testing, pharmacy benefit strategy, and generic pharmaceutical aggregation—does not align with the narrow pharmaceutical-ingredient scope that the commodity code represents.

The geographic spread of recent activity extends across Texas and the Upper Midwest (Minnesota and Oregon through MMCAP), but these jurisdictions are pursuing generalist pharmaceutical sourcing, cooperative purchasing frameworks, and clinical services rather than purchasing specific pharmaceutical active ingredients. State and local procurement under this code does not show concentrated activity focused on rebamipide itself; the code appears quiet relative to actual buying patterns. Business development professionals should verify whether rebamipide procurement actually occurs through state and local channels or whether this code assignment reflects a taxonomy mismatch in the opportunities system. The mismatch suggests that tracking this Commodity code for market signals or bid strategy would not yield actionable recent opportunities aligned with the product's actual scope.